DE69535883D1 - Muteine von ifn-beta - Google Patents

Muteine von ifn-beta

Info

Publication number
DE69535883D1
DE69535883D1 DE69535883T DE69535883T DE69535883D1 DE 69535883 D1 DE69535883 D1 DE 69535883D1 DE 69535883 T DE69535883 T DE 69535883T DE 69535883 T DE69535883 T DE 69535883T DE 69535883 D1 DE69535883 D1 DE 69535883D1
Authority
DE
Germany
Prior art keywords
ifn
beta
those
muteins
recombinant dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69535883T
Other languages
English (en)
Inventor
Susan E Goelz
Richard L Cate
E Pingchang Chow
R Blake Pepinsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DE69535883D1 publication Critical patent/DE69535883D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/565IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
DE69535883T 1994-03-15 1995-03-13 Muteine von ifn-beta Expired - Lifetime DE69535883D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/213,448 US5545723A (en) 1994-03-15 1994-03-15 Muteins of IFN-β
PCT/US1995/003206 WO1995025170A1 (en) 1994-03-15 1995-03-13 NOVEL MUTEINS OF IFN-$g(b)

Publications (1)

Publication Number Publication Date
DE69535883D1 true DE69535883D1 (de) 2008-12-24

Family

ID=22795174

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69535883T Expired - Lifetime DE69535883D1 (de) 1994-03-15 1995-03-13 Muteine von ifn-beta

Country Status (12)

Country Link
US (2) US5545723A (de)
EP (1) EP0750668B1 (de)
JP (2) JP3822903B2 (de)
AT (1) ATE414152T1 (de)
AU (1) AU695208B2 (de)
CA (1) CA2185352C (de)
DE (1) DE69535883D1 (de)
DK (1) DK0750668T3 (de)
FI (1) FI120356B (de)
NO (1) NO318989B1 (de)
NZ (2) NZ283217A (de)
WO (1) WO1995025170A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE270899T1 (de) * 1996-12-24 2004-07-15 Biogen Inc Stabile flüssige interferon-zubereitungen
IL142350A0 (en) * 1998-10-16 2002-03-10 Biogen Inc Interferon-beta fusion proteins and pharmaceutical compositions containing the same
SG2008070138A (en) * 1998-10-16 2017-08-30 Biogen Ma Inc Polymer conjugates of interferon beta- 1a and their uses
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7431921B2 (en) * 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
AU783208B2 (en) * 1999-12-09 2005-10-06 Novartis Vaccines And Diagnostics, Inc. Method for administering a cytokine to the central nervous system and the lymphatic system
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
MXPA03007619A (es) 2001-02-27 2003-12-04 Maxygen Aps Nuevas moleculas similares a interferon beta.
WO2002072019A2 (en) * 2001-03-13 2002-09-19 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
AU2002326991A1 (en) * 2001-09-18 2003-04-01 Chiron Corporation Methods for treating multiple sclerosis
EP2279755B1 (de) 2001-10-10 2014-02-26 ratiopharm GmbH Neumodulierung und Glykokonjugation von Fibroblasten-Wachstumsfaktor (FGF)
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EP2322229B1 (de) 2001-10-10 2016-12-21 Novo Nordisk A/S Neumodulierung und Glykokonjugation von Faktor IX
ATE466085T1 (de) * 2002-09-09 2010-05-15 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
MXPA05003243A (es) * 2002-09-27 2005-09-12 Biogen Idec Inc Terapias para polineuropatia desmielinizante inflamatoria cronica usando interferon-beta.
EP1581631A4 (de) * 2002-10-01 2007-09-05 Xencor Inc Interferonvarianten mit verbesserteneigenschaften
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
CN103755800B (zh) 2004-02-02 2016-02-24 Ambrx公司 经修饰的人类生长激素多肽与其用途
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
DOP2006000117A (es) * 2005-05-19 2007-11-30 Schering Ag Terapia génica de interferon-beta usando un sistema mejorado de expresión regulada
GT200600209A (es) * 2005-05-19 2007-01-03 Schering Ag Tratamiento de enfermedades usando un sistema mejorado de expresion regulada
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
EP1917276B1 (de) * 2005-08-26 2018-03-21 Ares Trading S.A. Verfahren zur herstellung von glykosyliertem interferon-beta
US20080038224A1 (en) * 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
WO2008125222A2 (en) * 2007-04-11 2008-10-23 Bayer Schering Pharma Aktiengesellschaft New modulation molecules for an improved regulated expression system
WO2008134406A1 (en) * 2007-04-25 2008-11-06 The Board Of Trustees Of The Leland Stanford Junior University Ischemia-induced neovascularization is enhanced by hcns-sc transplantation
BRPI0810622A2 (pt) * 2007-05-02 2020-10-13 Ambrx, Inc. polipeptídeos de interferon beta modificados e seus usos
US8273561B2 (en) * 2007-10-05 2012-09-25 Nuron Biotech, Inc. High pressure treatment of aggregated interferons
WO2010075500A1 (en) 2008-12-23 2010-07-01 Stemcells California, Inc Target populations of oligodendrocyte precursor cells and methods of making and using same
WO2019073315A1 (en) 2017-10-09 2019-04-18 Mansour Poorebrahim ANALOGUE PEPTIDE OF INTERFERON-BETA

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI88175C (fi) * 1980-04-03 1993-04-13 Biogen Inc Rekombinant-dna-molekyler och foerfaranden foer framstaellning av polypeptider liknande humant -interferon
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
DE3683910D1 (de) * 1986-09-05 1992-03-26 Cetus Corp Oxidationsresistente muteine von beta-interferon, deren herstellung und diese muteine enthaltende praeparate.
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
IL92124A (en) * 1988-10-28 1996-10-31 Sidney Pestka Recombinant proteins modified to contain post-phosphorylation that do not occur in nature
CA2131550A1 (en) * 1992-02-05 1993-08-19 Andrew Zalewski Interferon gene therapy for the treatment of vascular disorders

Also Published As

Publication number Publication date
NZ283217A (en) 1998-05-27
NZ329970A (en) 2000-01-28
US5545723A (en) 1996-08-13
NO318989B1 (no) 2005-05-30
FI120356B (fi) 2009-09-30
US6127332A (en) 2000-10-03
CA2185352A1 (en) 1995-09-21
ATE414152T1 (de) 2008-11-15
FI963630A (fi) 1996-09-13
CA2185352C (en) 2005-02-22
JPH10500563A (ja) 1998-01-20
NO963837D0 (no) 1996-09-13
EP0750668B1 (de) 2008-11-12
FI963630A0 (fi) 1996-09-13
DK0750668T3 (da) 2009-03-02
MX9604073A (es) 1997-12-31
EP0750668A1 (de) 1997-01-02
JP3822903B2 (ja) 2006-09-20
NO963837L (no) 1996-11-14
WO1995025170A1 (en) 1995-09-21
AU2120295A (en) 1995-10-03
JP2006199711A (ja) 2006-08-03
AU695208B2 (en) 1998-08-06

Similar Documents

Publication Publication Date Title
ATE414152T1 (de) Muteine von ifn-beta
DK75694A (da) Tumornecrosefaktor og derivater og mutantformer deraf, fremgangsmåde til fremstilling deraf, DNA som koder derfor, replicerbar udtrykkelsesvektor indeholdende DNA'en og celle transformeret dermed samt præparater omfattende tumornecrosefaktoren
NO914541L (no) Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner
RU95115239A (ru) Аналог эритропоэтина
DK0880970T3 (da) Anvendelse af farmaceutiske præparater der omfatter et anticytokin, til behandling af dissemineret sklerose
ATE91630T1 (de) Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren.
WO2002074980A3 (en) Muteins of hypoxia inducible factor alpha and methods of use thereof
DE69229862T2 (de) Cysteinfreie il-6 mutanten
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
ES2080060T3 (es) Proteinas que tienen actividad de union a interferon-gamma.
DE3788899D1 (de) Intraläsionale Behandlung von Basalzellenkarzinoma mittels rekombinanten humanen alpha-Interferons.
NZ332690A (en) Stimulation of host defence mechanisms against viral challenges using interferon
DE59208025D1 (de) Neue thrombininhibitorische proteine aus landblutegeln
IL92495A0 (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
Goelz et al. Muteins of IFN-beta
DE69839150D1 (de) Intrazelluläre glukocortikoid-induzierte leucin-zipper modulatoren von mechanismen des apoptotischen zelltodes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition